# Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.

> **NCT02113267** · PHASE2 · TERMINATED · sponsor: **Mogens Bove** · enrollment: 40 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Mometasone furoate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02113267
- **Lead sponsor:** Mogens Bove
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included).
- **Last updated:** 2018-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113267, "Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02113267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*